The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

Dexcom, Inc. DXCM recently announced that its G6 continuous glucose monitoring (“CGM”) System is now covered by the Non-Insured Health Benefits (“NIHB”) program for diabetics aged between two and 19 ...

DexCom, Inc. DXCM recently announced that its G6 continuous glucose monitoring (“CGM”) System will be available to diabetic military members, their families and retirees as a TRICARE brand-name ...

Dexcom G6 was the first Continuous Glucose Monitoring (CGM) System to be officially listed by the NIHB Drug Benefit program. BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), ...

DexCom, Inc. DXCM announced that the FDA has approved its G6 Pro Continuous Glucose Monitoring (“CGM”) System for use on patients (aged two years and up). This further fortifies DexCom’s foothold in ...

The use of CGM has been growing among people without diabetes, including those with prediabetes, particularly with the ...

Dexcom, a global leader in real time continuous glucose monitoring for people with diabetes, is releasing the Dexcom G6 mobile app in Spanish, available immediately for users with a compatible iOS (v1 ...

The Australian government has expanded the subsidised access to the latest generation of Dexcom's continuous glucose monitoring device, Dexcom G6, for diabetic Australians. This comes as the previous ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has granted clearance to a ...